Related Experiment Video
Updated: Jun 28, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced
Chia-Hwa Lee1,2,3,4, Kai-Wen Hsu5,6,7, Yao-Yu Hsieh8,9
1School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, New Taipei City 23561, Taiwan.
Abstract:
The management of chronic myelogenous leukemia (CML) has seen significant progress with the introduction of tyrosine kinase inhibitors (TKIs), particularly Imatinib. However, a notable proportion of CML patients develop resistance to Imatinib, often due to the persistence of leukemia stem cells and resistance mechanisms independent of BCR::ABL1 This study investigates the roles of IL6R, IL7R, and MYC in Imatinib resistance by employing CRISPR/Cas9 for gene editing and the Non-Invasive Apoptosis Detection Sensor version 2 (NIADS v2) for apoptosis assessment. The results indicate that Imatinib-resistant K562 cells (K562-IR) predominantly express IL6R, IL7R, and MYC, with IL6R and MYC playing crucial roles in cell survival and sensitivity to Imatinib. Conversely, IL7R does not significantly impact cytotoxicity, either alone or in combination with Imatinib. Further genetic editing experiments confirm the protective functions of IL6R and MYC in K562-IR cells, suggesting their potential as therapeutic targets for overcoming Imatinib resistance in CML. This study contributes to understanding the mechanisms of Imatinib resistance in CML, proposing IL6R and MYC as pivotal targets for therapeutic strategies. Moreover, the utilization of NIADS v2 enhances our capability to analyze apoptosis and drug responses, contributing to a deeper understanding of CML pathogenesis and treatment options.
Insights
Interleukin-6 receptor (IL6R) and MYC are key drivers of imatinib resistance in chronic myelogenous leukemia (CML). Targeting IL6R and MYC may overcome resistance in CML patients.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Research
Background:
- Tyrosine kinase inhibitors (TKIs) like imatinib have advanced chronic myelogenous leukemia (CML) management.
- A significant subset of CML patients exhibit resistance to imatinib, often linked to leukemia stem cells and BCR::ABL1-independent mechanisms.
Purpose of the Study:
- To investigate the roles of IL6R, IL7R, and MYC in imatinib resistance in CML.
- To explore potential therapeutic targets for overcoming imatinib resistance.
Main Methods:
- Utilized CRISPR/Cas9 gene editing to modify gene expression.
- Employed the Non-Invasive Apoptosis Detection Sensor version 2 (NIADS v2) for apoptosis assessment.
- Analyzed imatinib-resistant K562 cells (K562-IR) for gene expression and drug sensitivity.
Main Results:
- Imatinib-resistant K562 cells predominantly express IL6R, IL7R, and MYC.
- IL6R and MYC significantly contribute to cell survival and imatinib sensitivity.
- IL7R expression did not substantially affect cytotoxicity, alone or with imatinib.
- Gene editing confirmed the protective roles of IL6R and MYC in K562-IR cells.
Conclusions:
- IL6R and MYC are pivotal targets for overcoming imatinib resistance in CML.
- Targeting IL6R and MYC presents a promising therapeutic strategy for CML patients resistant to imatinib.
- NIADS v2 is a valuable tool for analyzing apoptosis and drug responses in CML research.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018